BRPI0412668A - peptìdeos antigênicos de ar - Google Patents

peptìdeos antigênicos de ar

Info

Publication number
BRPI0412668A
BRPI0412668A BRPI0412668-8A BRPI0412668A BRPI0412668A BR PI0412668 A BRPI0412668 A BR PI0412668A BR PI0412668 A BRPI0412668 A BR PI0412668A BR PI0412668 A BRPI0412668 A BR PI0412668A
Authority
BR
Brazil
Prior art keywords
antigenic peptides
protein
receptor
chain
complement
Prior art date
Application number
BRPI0412668-8A
Other languages
English (en)
Inventor
Nikolaos Berntenis
Gerrit Buurman
Harald Kropshofer
Bernd Christian Mueller
Sebastian Thomas Spindeldreher
Anne Vogt
Werner Zolg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0412668A publication Critical patent/BRPI0412668A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PEPTìDEOS ANTIGêNICOS DE AR". A presente invenção refere-se a novos peptídeos antigênicos da classe II do MHC naturalmente processados os quais se originam de tiol reductase lisossómica interferon-<sym>-induzível, integrina beta-2, 3-quínase de fosfatidilinositol-4,5-bisfosfato, ativador de plasminogênio do tipo uroquínase, região V-III de cadeia pesada de imunoglobulina (V~ H~26), proteína DJ-1, apolipoproteína B-100, subunidade 8 regulatória de não-ATPase de proteassoma 26S, receptor de interleucina-1, fibromodulina, receptor de GM-CSF/IL3/IL-5, nexina 3 de seleção, cadeia H4 pesada de inibidor de inter-<244>-tripsina, complemento C4, complemento C3 (<244>-cadeia), complemento C3 (<225>-cadeia), proteína 3 rica em ácido glutâmico do domínio de ligação SH3, proteína 1 interleucina-4-induzida, hemopexina, proteína de Hsc70-interação, cadeia (li) invariável, proteína 2 respondedora ao receptor de ácido retinóico, fibroneotina, catepsina B, tripeptidil-peptidase II, legumaína, receptor do fator de ativação plaquetária, poli-alfa-2.8-sialiltransferase e proteína Rab-11B rasrelacionada. Também proporcionados são esses peptídeos antigênicos e as proteínas das quais eles são derivados como marcadores para AR erosiva e/ou não-erosiva. Além disso, esses peptídeos antigênicos ligados à moléculas da classe II do MHC, anticorpos reativos aos referidos peptídeos antigênicos, ácidos nucléicos que codificam os referidos peptídeos antigênicos e estruturas de ácido nucléico, células hospedeiras e métodos para expressão dos referidos peptídeos antigênicos são proporcionados. Os peptídeos antigênicos da invenção podem ser usados como marcadores no diagnóstico de AR e em terapia como vacinas anti-AR.
BRPI0412668-8A 2003-08-07 2004-07-30 peptìdeos antigênicos de ar BRPI0412668A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03017551 2003-08-07
PCT/EP2004/008609 WO2005014622A2 (en) 2003-08-07 2004-07-30 Ra antigenic peptides

Publications (1)

Publication Number Publication Date
BRPI0412668A true BRPI0412668A (pt) 2006-09-26

Family

ID=34130049

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412668-8A BRPI0412668A (pt) 2003-08-07 2004-07-30 peptìdeos antigênicos de ar

Country Status (14)

Country Link
US (1) US20080193457A1 (pt)
EP (1) EP1654272B1 (pt)
JP (1) JP4532486B2 (pt)
KR (1) KR100769338B1 (pt)
CN (1) CN100584858C (pt)
AT (1) ATE442377T1 (pt)
AU (1) AU2004263303A1 (pt)
BR (1) BRPI0412668A (pt)
CA (1) CA2532721A1 (pt)
DE (1) DE602004023096D1 (pt)
ES (1) ES2330748T3 (pt)
MX (1) MXPA06001326A (pt)
RU (1) RU2359974C2 (pt)
WO (1) WO2005014622A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715343B1 (en) 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
WO2007111938A2 (en) 2006-03-23 2007-10-04 The General Hospital Corporation Inflammation-inhibitory serum factors and uses thereof
FR2900155B1 (fr) * 2006-04-21 2008-06-27 Diana Naturals Sa Hydrolisat de cartilage aviaire, procede d'obtention et utilisations
KR100956893B1 (ko) * 2006-09-25 2010-05-11 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
WO2008120684A1 (ja) * 2007-03-30 2008-10-09 Yamaguchi University 急性中枢神経障害の予後判定方法
EP2056110A1 (en) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2016009436A1 (en) 2014-07-15 2016-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Isolated polypeptides of cd44 and uses thereof
CN112739713A (zh) * 2018-06-25 2021-04-30 华盛顿大学 有力的且选择性的白介素模拟物的从头设计
CN111748580B (zh) * 2019-03-28 2022-09-13 百奥泰生物制药股份有限公司 一种检测免疫检查点抗体活性的方法
PL4010006T3 (pl) * 2019-08-09 2024-04-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Kompleksy peptydów hla-dr/cii w leczeniu zapalenia stawów
WO2022188025A1 (zh) * 2021-03-09 2022-09-15 台北医学大学 抗修饰胜肽抗体及其检测关节炎之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204780D0 (en) * 1992-03-05 1992-04-15 Smith Geoffrey L Vaccinia vectors,vaccinia genes,and expression products thereof;pharmaceuticals,reagents and methods
EP1290217A2 (en) * 2000-02-04 2003-03-12 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
CA2457819A1 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2003058021A2 (de) * 2002-01-11 2003-07-17 Xantos Biomedicine Ag Neue apoptose-induzierende dna-sequenzen
EP1826217B1 (en) * 2002-10-02 2010-07-21 F.Hoffmann-La Roche Ag Method for identification of antigenic peptides

Also Published As

Publication number Publication date
RU2359974C2 (ru) 2009-06-27
CA2532721A1 (en) 2005-02-17
KR20060033923A (ko) 2006-04-20
EP1654272A2 (en) 2006-05-10
MXPA06001326A (es) 2006-05-04
KR100769338B1 (ko) 2007-10-24
WO2005014622A3 (en) 2005-05-06
ES2330748T3 (es) 2009-12-15
RU2006106729A (ru) 2007-09-20
US20080193457A1 (en) 2008-08-14
CN1845936A (zh) 2006-10-11
WO2005014622A2 (en) 2005-02-17
AU2004263303A1 (en) 2005-02-17
DE602004023096D1 (de) 2009-10-22
ATE442377T1 (de) 2009-09-15
JP2007527226A (ja) 2007-09-27
CN100584858C (zh) 2010-01-27
JP4532486B2 (ja) 2010-08-25
EP1654272B1 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
Feldman et al. Model of alpha 2-macroglobulin structure and function.
BRPI0412668A (pt) peptìdeos antigênicos de ar
Nagase et al. Ovostatin: a novel proteinase inhibitor from chicken egg white. I. Purification, physicochemical properties, and tissue distribution of ovostatin.
CN101035439B (zh) 通过亲和色谱法进行的连续蛋白质分离和提纯方案
Becker-Pauly et al. Proteomic analyses reveal an acidic prime side specificity for the astacin metalloprotease family reflected by physiological substrates
Nilsson et al. Protein assembly by orthogonal chemical ligation methods
NO20065861L (no) Metode for a stabilisere proteiner
ATE528016T1 (de) Virusähnliche partikel als paramyxovirus- impfstoffe
WO2007053188A3 (en) Production of multivalent virus like particles
ES2379283T3 (es) Proteínas de unión a albúmina sérica
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
WO2003106684A3 (en) PROCESS FOR THE SIMULTANEOUS PRODUCTION OF SEVERAL PROTEINS; VECTORS AND CELLS USED IN THIS PROCESS
Shaeffer et al. Degradation of monoubiquitinated. alpha.-globin by 26s proteasomes
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
TW200510450A (en) Soluble fragments of the SARS-CoV spike glycoprotein
ATE449790T1 (de) Rekombinante gelatinepartikel für die zelladhäsion
WO2002070652A3 (en) Novel molecules of the card-related protein family and uses thereof
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
Berven et al. Multiple polypeptide forms observed in two‐dimensional gels of Methylococcus capsulatus (Bath) polypeptides are generated during the separation procedure
DK1576157T3 (da) Fluorescerende proteiner fra Copepode-arter og fremgangsmåder til anvendelse af samme
Li et al. Purification and characterization of a cysteine protease inhibitor from chum salmon (Oncorhynchus keta) plasma
Grubman et al. In vitro protein-synthesizing activity of vesicular stomatitis virus-infected cell extracts
WO2009074318A3 (en) Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
ATE327251T1 (de) Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.